{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:11:42Z","timestamp":1767183102139,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH\u20112019\u2011C\u2011028","CSH\u20112020\u2011C\u2011029","CSH-2021-C025","CSH-2022-C026"],"award-info":[{"award-number":["CSH\u20112019\u2011C\u2011028","CSH\u20112020\u2011C\u2011029","CSH-2021-C025","CSH-2022-C026"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00428-022-03285-9","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T08:02:43Z","timestamp":1646035363000},"page":"1023-1030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing the 2017 ASCO\/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO\/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma"],"prefix":"10.1007","volume":"480","author":[{"given":"Wan-Ru","family":"Chao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwo-Tarng","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"3285_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1813254","volume":"380","author":"P Morice","year":"2019","unstructured":"Morice P, Gouy S, Leary A (2019) Mucinous Ovarian Carcinoma. N Engl J Med 380:1256\u20131266. https:\/\/doi.org\/10.1056\/NEJMra1813254","journal-title":"N Engl J Med"},{"key":"3285_CR2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/PAS.0000000000000268","volume":"38","author":"WR Chao","year":"2014","unstructured":"Chao WR, Lee MY, Lin WL, Koo CL, Sheu GT, Han CP (2014) Assessing the HER2 status in mucinous epithelial ovarian carcinoma on the basis of the 2013 ASCO\/CAP guideline update. Am J Surg Pathol 38:1227\u20131234. https:\/\/doi.org\/10.1097\/PAS.0000000000000268","journal-title":"Am J Surg Pathol"},{"key":"3285_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/1471-2407-9-433","volume":"9","author":"JN McAlpine","year":"2009","unstructured":"McAlpine JN, Wiegand KC, Vang R et al (2009) Overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9:433","journal-title":"BMC Cancer"},{"key":"3285_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1136\/jclinpath-2011-200082","volume":"64","author":"B Yan","year":"2011","unstructured":"Yan B, Choo SN, Mulyadi P et al (2011) Dual-colour HER2\/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 64:1097\u20131101","journal-title":"J Clin Pathol"},{"key":"3285_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/path.4088","volume":"229","author":"MS Anglesio","year":"2013","unstructured":"Anglesio MS, Kommoss S, Tolcher MC et al (2013) Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229:111\u2013120","journal-title":"J Pathol"},{"key":"3285_CR6","doi-asserted-by":"publisher","first-page":"e61565","DOI":"10.1371\/journal.pone.0061565","volume":"8","author":"WY Chay","year":"2013","unstructured":"Chay WY, Chew SH, Ong WS et al (2013) HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One. 8:e61565","journal-title":"PLoS One."},{"issue":"4","key":"3285_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C et al (2017) HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446\u2013464. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","journal-title":"J Clin Oncol"},{"key":"3285_CR8","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"3285_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","volume":"17","author":"DP English","year":"2013","unstructured":"English DP, Roque DM, Santin AD (2013) HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 17:85\u201399. https:\/\/doi.org\/10.1007\/s40291-013-0024-9","journal-title":"Mol Diagn Ther"},{"key":"3285_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ygyno.2014.09.003","volume":"135","author":"E Teplinsky","year":"2014","unstructured":"Teplinsky E, Muggia F (2014) Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecol Oncol 135:364\u2013370. https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.003","journal-title":"Gynecol Oncol"},{"key":"3285_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142135","volume":"10","author":"WR Chao","year":"2015","unstructured":"Chao WR, Lee MY, Ruan A et al (2015) Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method. PLoS ONE 10:e0142135. https:\/\/doi.org\/10.1371\/journal.pone.0142135","journal-title":"PLoS ONE"},{"key":"3285_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000171","volume":"93","author":"CK Chen","year":"2014","unstructured":"Chen CK, Lee MY, Lin WL et al (2014) A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer. Medicine (Baltimore) 93:e171. https:\/\/doi.org\/10.1097\/MD.0000000000000171","journal-title":"Medicine (Baltimore)"},{"key":"3285_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"3285_CR14","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG et al (2013) American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984","journal-title":"J Clin Oncol"},{"key":"3285_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/diagnostics10010052","volume":"10","author":"A Babaier","year":"2020","unstructured":"Babaier A, Ghatage P (2020) Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics (Basel) 10:52. https:\/\/doi.org\/10.3390\/diagnostics10010052","journal-title":"Diagnostics (Basel)"},{"key":"3285_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"3285_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","volume":"156","author":"KL Gorringe","year":"2020","unstructured":"Gorringe KL, Cheasley D, Wakefield MJ et al (2020) Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol 156:552\u2013560. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.015","journal-title":"Gynecol Oncol"},{"key":"3285_CR18","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","volume":"30","author":"KL Jhaveri","year":"2019","unstructured":"Jhaveri KL, Wang XV, Makker V et al (2019) Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 30:1821\u20131830. https:\/\/doi.org\/10.1093\/annonc\/mdz291","journal-title":"Ann Oncol"},{"key":"3285_CR19","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/bcr3674","volume":"16","author":"M Sun","year":"2014","unstructured":"Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y (2014) Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res 16:R61. https:\/\/doi.org\/10.1186\/bcr3674","journal-title":"Breast Cancer Res"},{"key":"3285_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/hum.2014.006","volume":"25","author":"E Lanitis","year":"2014","unstructured":"Lanitis E, Smith JB, Dangaj D et al (2014) A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther 25:730\u2013739. https:\/\/doi.org\/10.1089\/hum.2014.006","journal-title":"Hum Gene Ther"},{"key":"3285_CR21","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.3390\/ijms22073495","volume":"22","author":"KM Terlikowska","year":"2021","unstructured":"Terlikowska KM, Dobrzycka B, Terlikowski SJ (2021) Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. Int J Mol Sci 22:3495. https:\/\/doi.org\/10.3390\/ijms22073495","journal-title":"Int J Mol Sci"},{"key":"3285_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/cancers13040840","volume":"13","author":"G Schepisi","year":"2021","unstructured":"Schepisi G, Casadei C, Toma I et al (2021) Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy. Cancers (Basel) 13:840. https:\/\/doi.org\/10.3390\/cancers13040840","journal-title":"Cancers (Basel)"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03285-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T05:09:17Z","timestamp":1650604157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03285-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3285"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03285-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"type":"print","value":"0945-6317"},{"type":"electronic","value":"1432-2307"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}